Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect
Rhea-AI Summary
WW (NASDAQ: WW) will offer Eli Lilly’s newly FDA-approved oral GLP-1 Foundayo (orforglipron) through its Med+ program beginning April 9, 2026. Med+ members gain access to once-daily, oral treatment with board-certified clinician care, insurance support, and the Weight Watchers GLP-1 Success behavioral program.
Self-pay pricing for Foundayo starts at $149 per month for the lowest dose, with price varying by dose. Weight Watchers reports members who engaged the GLP-1 Success Program for 12 months lost 29.1% more body weight on average than non-engaged members.
Positive
- Access expanded to FDA-approved oral GLP-1 Foundayo via Med+
- $149/month self-pay entry price for lowest dose
- Engagement with GLP-1 Success Program linked to 29.1% greater weight loss over 12 months
Negative
- Self-pay pricing starts at $149/month, which may affect affordability for some members
News Market Reaction – WW
In the Apr 9 session, WW gained 0.88%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.8% during that session. Argus tracked a trough of -11.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Board appointments | Positive | -3.3% | Added two independent directors to support strategic transformation. |
| Mar 31 | Drug pricing update | Positive | +4.0% | Announced best-in-market self-pay Wegovy pricing and subscription options. |
| Mar 16 | Earnings results | Positive | +4.6% | Reported Q4/FY 2025, exceeded 2025 guidance and issued 2026 outlook. |
| Mar 11 | GLP-1 outcomes data | Positive | +1.2% | Released GLP‑1 report showing significantly greater weight loss with support. |
| Feb 27 | Earnings call notice | Neutral | +2.5% | Scheduled Q4 and FY 2025 earnings release and conference call date. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive and strategic updates have more often seen supportive price reactions, with one notable divergence on governance/board news.
Over the last six weeks, WW has focused on GLP‑1‑driven growth and governance changes. Earnings on Mar 16, 2026 showed $163 million Q4 revenue and guidance for $620–$635 million 2026 revenue, with a positive price reaction. Subsequent GLP‑1 program data and improved Wegovy pricing also aligned with gains. In contrast, the Apr 7, 2026 board appointments coincided with a 3.25% decline. Today’s new Lilly GLP‑1 access fits the ongoing pivot toward clinical Med+ and GLP‑1 partnerships.
Key Terms
glp-1 medical
fda-approved regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The addition of Foundayo® (orforglipron) gives Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for weight loss
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company’s newly FDA-approved oral GLP-1, Foundayo® (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new once-daily, injection-free option for adults with obesity or overweight with weight-related medical problems and further expands the company’s growing portfolio of FDA-approved oral GLP-1 treatments, all within a clinically supported program designed to help them succeed.
Through Weight Watchers Med+, clinically eligible members will be able to access this newly approved medication alongside care from board-certified clinicians, insurance support, and additional tools designed to support the treatment journey. All Med+ members also receive direct access to the Weight Watchers GLP-1 Success program to support them before, during, and after medication use.
For members choosing self-pay, pricing will start at
“As the weight health landscape evolves, it’s important that people have access to a broad range of FDA-approved treatment options that reflect different needs, preferences, and routines,” said Scott Honken, Chief Commercial Officer at Weight Watchers. “With this new offering, Weight Watchers is expanding access to a new FDA-approved option through a trusted platform built to help members access treatment with clinical support and ongoing guidance.”
Weight Watchers Med+ enables access, if appropriate, to medications like Foundayo with an integrated support model designed to help members navigate treatment in real life. Among Med+ members prescribed a GLP-1, those who regularly engaged with the GLP-1 Success Program for 12 months lost
“At Lilly, we are committed to expanding access to innovative treatments that meet the diverse needs of people living with obesity,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Lilly. “Expanding choice means more people can find a treatment pathway that meets patients where they are in their journey.”
“As more and more people are seeking GLP-1 medications, it is more critical than ever for comprehensive care models to support lasting outcomes,” said Mike Mason, a member of Weight Watchers’ Board of Directors and former President of Eli Lilly’s Diabetes and Obesity business. “Weight Watchers stands at the forefront of this evolution with its clinical credibility, behavior change expertise, and community support.”
ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.
For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com
For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com
